📈 Stocks · US

Pfizer Stock PFE · Forecast & Analysis

Stocks US ISIN US7170811035
News situation · News, 30 days · no price data
▬ Neutral weak Data coverage thin
Price no dataTrend no price dataNews none in 30 days
  • Pfizer trades near $28 with evidence pulling both ways: a Q2 beat and raised guidance on one side, heavy debt and a patent cliff on the other.
  • The roughly 6.2% dividend yield is covered by 2026 EPS guidance of $2.80-$3.00, though payouts currently exceed free cash flow.
  • With no technical signals active, the neutral verdict rests entirely on fundamental evidence that is evenly split.
  • Weight-loss candidates PF'3944 and berobenatide, with a potential 2028 launch, are the main long-term swing factor.
News situation · 0 items / 30 D
▬ Neutral weak Data coverage thin
AI-generated · as of November 7, 2026
News, 30 days
Neutral
Outlook

Outlook for Pfizer Inc.

Direction, typical moves and upcoming dates from our own price, news and calendar data, recalculated on every visit. An assessment, not investment advice.

What drives it
  • The Q2 beat and raised full-year revenue guidance provide support for shares consolidating near $28.
  • A forward P/E of 10 and a yield above 6% position the stock as a deep-value income holding.
  • Pipeline candidates PF'3944 and berobenatide, with potential launch in 2028, underpin the longer-term growth case.
  • The stock has outperformed the S&P 500 year-to-date while paying a high dividend.
What argues against it
  • An approaching patent cliff could erode revenue that the current valuation assumes will be replaced.
  • Dividend payouts exceed free cash flow, and Seagen acquisition debt limits financial flexibility.
  • Declining kindergarten vaccination rates under current health policy weigh on vaccine revenue.
  • High-impact CPI releases due in three days could shift the macro backdrop and healthcare sentiment.
Coming up
  • US: CB Consumer Confidence Index · expected 91.5, previous 91.7
  • US: PCE price index, Jobless claims, GDP · expected 3.1%, previous 3.1%
All dates ↓ All times UTC.

Economic data for PFE

Full calendar

Recently released

  • November 20, 2026USDMichigan Consumer Sentiment●●●Actual 51.5Forecast 51.0Previous 51.0better than expected for USD2 days ago

Coming up

  • November 24, 2026USDCB Consumer Confidence Index●●●Forecast 91.5Previous 91.7in 1 day
  • November 25, 2026USDPCE Price Index m/m●●●Forecast 0.4%Previous 0.5%in 2 days
  • November 25, 2026USDInitial Jobless Claims●●●in 2 days
  • November 25, 2026USDCore PCE Price Index y/y●●●Forecast 3.1%Previous 3.1%in 2 days
  • November 25, 2026USDCore PCE Price Index m/m●●●Forecast 0.3%Previous 0.3%in 2 days
  • November 25, 2026USDGDP Sales q/q●●●Forecast 1.7%Previous 1.7%in 2 days
  • November 25, 2026USDGDP q/q●●●Forecast 3.4%Previous 3.4%in 2 days
  • November 25, 2026USDDurable Goods Orders m/m●●●Forecast -0.7%Previous 1.8%in 2 days

All times UTC. Assessed against the consensus forecast, otherwise against the previous value.

Signal history

Both worlds over time

Technical and news signals of the last 90 days on one timeline.

Bullish ▲Bearish ▼08.09. · News signal · Impact 3/1008.09. · News signal · Impact 8/1011.09. · News signal · Impact 5/1011.09. · News signal · Impact 3/1014.09. · News signal · Impact 5/1015.09. · News signal · Impact 4/1016.09. · News signal · Impact 2/1018.09. · News signal · Impact 7/1020.09. · News signal · Impact 1/1020.09. · News signal · Impact 7/1020.09. · News signal · Impact 4/1023.09. · News signal · Impact 5/1008.10. · News signal · Impact 2/10
90 days ago today
Technical signal News signal Size = strength
Full analysis

In-depth analysis of Pfizer Inc.

AI-generated · as of November 7, 2026

Pfizer's reading is neutral, and the picture behind it is genuinely two-sided. The company beat Q2 estimates and raised full-year revenue guidance on strong non-COVID growth and deeper cost cuts, yet the stock has merely consolidated near $28, a muted reaction that keeps the good news from carrying much weight.

There are no fresh technical signals on any timeframe, so the verdict rests on fundamentals, and those are split. A dividend yield of about 6.2% covered by 2026 adjusted EPS guidance of $2.80-$3.00, plus a forward P/E of 10, argue for value; debt from the Seagen acquisition, dividend payouts exceeding free cash flow and an approaching patent cliff argue against it. Declining kindergarten vaccination rates under current health policy pressure vaccine revenue, though the diversified portfolio softens the blow. Pipeline candidates PF'3944 and berobenatide, potentially launching in 2028, are the long-term swing factor. Company-specific news is thin, with the only recent item a routine industry appearance that carries no financial weight, so the fundamental summary and the macro backdrop do most of the talking. The result is balance rather than hidden conviction in either direction.

Frequently asked questions about Pfizer Inc.

Why is the verdict neutral when Pfizer just beat estimates and raised guidance?

The positive results were real but the market's reaction was muted, with shares consolidating near $28 rather than breaking higher. That tells you the beat is already priced in and that other worries, like debt from the Seagen acquisition, payouts exceeding free cash flow and the approaching patent cliff, are weighing just as heavily. When good news no longer moves a stock, the balance of conviction is even, which is what a neutral reading reflects.

Is the dividend at risk?

The 2026 adjusted EPS guidance of $2.80-$3.00 covers the $1.72 annualized dividend, so on an earnings basis the payout looks supported. The concern is cash flow: dividend payments currently exceed free cash flow, and debt from the Seagen acquisition adds interest burdens. Neither makes the dividend immediately unsafe, but it means income investors should watch cash-flow trends and any progress on cost cuts rather than assume the yield is effortless.

What could push the stock out of its current range?

Three things stand out. First, news on the weight-loss pipeline, PF'3944 and berobenatide, whose potential 2028 launch is the clearest growth catalyst. Second, progress or setbacks on patent cliff mitigation and cost-cutting, which drive the mid-term view. Third, sector rotation in healthcare and the broader market, which the stock has so far outperformed year-to-date despite the mixed fundamental picture.

How much do vaccine demand trends matter for Pfizer?

They matter but not decisively. Declining kindergarten vaccination rates under current health policy pressure vaccine revenue, which is a genuine headwind. However, Pfizer's portfolio is diversified across non-COVID products and pipeline candidates, which offsets part of the impact. That is why this risk shapes the cautious longer-term view rather than dominating the verdict: it is one of several structural pressures, alongside debt and the patent cliff, rather than the single story of the stock.

Asset Snapshot

📝 Overview Generated automatically

PFE has been the subject of 14 signals across 14 articles in the last 365 days. Sentiment skews Bullish (43%).

Breakdown: 6 bullish, 2 bearish, 6 neutral.

Most-cited catalysts: RFK Jr. leading HHS with anti-vaccine stance (1×), CDC data shows falling kindergarten vaccination rates (1×), Strong year-to-date performance relative to the S&P 500 (1×). Most-cited risk factors: Pfizer's diversified portfolio offsets vaccine revenue decline (1×), Potential policy reversal or legal challenges (1×), Sector-specific headwinds in the pharmaceutical industry (1×).

Keep exploring

Related assets

Same category or comparable signal picture — each card opens the full cockpit.